This inventor holds 3 USPTO granted patents and 1 published patent application. Top assignee: Lupin, Inc.. Active years: 2014-2016.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2014-2016
Title: Bharat Raghunath Metkar: Innovator in Pharmaceutical Compositions
Introduction
Bharat Raghunath Metkar is a notable inventor based in Pune, India. He has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative compositions. With a total of 3 patents to his name, Metkar has established himself as a key figure in pharmaceutical innovation.
Latest Patents
Metkar's latest patents include groundbreaking formulations that enhance the efficacy of Cefixime. One of his patents describes a pharmaceutical suspension formulation comprising a dose greater than 100 mg/5 ml of Cefixime along with pharmaceutically acceptable excipients. Another patent focuses on a pharmaceutical suspension dosage form that contains greater than 80 mg/ml and not more than 150 mg/ml of Cefixime, also combined with suitable excipients. These innovations reflect his commitment to improving patient care through effective medication.
Career Highlights
Bharat Raghunath Metkar is currently associated with Lupin, Inc., a leading global pharmaceutical company. His work at Lupin has allowed him to collaborate with other talented professionals in the industry, further enhancing his contributions to pharmaceutical science.
Collaborations
Some of his notable coworkers include Makarand Krishnakumar Avachat and Shrenik Annasaheb Kole. Their collaborative efforts have played a significant role in advancing the research and development initiatives at Lupin.
Conclusion
Bharat Raghunath Metkar's innovative work in pharmaceutical compositions exemplifies the impact of dedicated inventors in the healthcare sector. His contributions continue to pave the way for advancements in medication formulations that benefit patients worldwide.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
